Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Hemodialysis Patients and Healthy Volunteers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211026002

Enrollment

130

Registered

2021-10-26

Start date

2021-06-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune response after ChAdOx1 nCoV-19 Vaccine in hemodialysis patients compared to healthy volunteers. Immune response, ChAdOx1 nCoV-19 Vaccine, Hemodialysis patients, wild-type, delta variant, antibody, T-cell response

Interventions

Hemodialysis patients who received 2 doses of ChAdOx1 nCoV-19 Vaccine,Healthy volunteers who received 2 doses of ChAdOx1 nCoV-19 Vaccine

Prevention,Prevention

Hemodialysis patients,Healthy volunteers

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult (age >= 18 years old), 2.Hemodialysis patients, 3. Recipients 2 doses of ChAdOx1 nCoV-19 vaccine

Exclusion criteria

Exclusion criteria: 1. Refuse to participate, 2.Infected with COVID-19 during the study period, 3. Recipients of intravenous immunoglobulin

Design outcomes

Primary

Measure	Time frame
Immunogenicity 2-6 weeks after vaccination Antibody response and T-cell response	—

Secondary

Measure	Time frame
Associated factors of antibody response After the results of immune response Statistical analysis,Associated factors of T-cell response After the results of immune response Statistical analysis,Safety and adverse reactions after vaccination After completion of each dose of vaccination Statistical analysis	—

Countries

Thailand

Contacts

Public ContactSiriorn Watcharananan

Praram 9 Hospital

orndoctor@yahoo.com66841108000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026